SLC5A2 and chronic kidney disease: Despite the use of evidence-based pharmacological therapies (conventional RAS blockers and emerging SGLT2 inhibitors), the mortality and morbidity rates of T2D and CKD remain high, thereby indicating residual pathological targets that are not covered by existing medications.